uploads/2016/11/Graph-5-8-1.png

Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix

By

Updated

Women’s health segment opportunity

While Neurocrine Biosciences (NBIX) invented and developed Elagolix through phase two trials, it’s currently being tested in phase three trials by AbbVie (ABBV). According to Truven Health Analytics, about 10% of women of reproductive age, or approximately 7.5 million women, in the US and Europe suffer from endometriosis. To know more about the deal between Neurocrine Biosciences and AbbVie related to Elagolix, please refer to Will Elagolix Make Neurocrine Biosciences a Key Women’s Health Name?

Article continues below advertisement

In the Jefferies 2016 London Healthcare Conference, it was also mentioned that an average timespan of about eight years passes before a woman suffering from endometriosis-related symptoms is diagnosed. Further, there are very limited options currently available on the market for the disease. High prevalence, limited alternative treatment options, and the significant burden of the disease are the key factors that make endometriosis an attractive market segment for Elagolix. To know more about the treatment options for endometriosis-associated pain, please refer to Elagolix May Become a Strong Growth Driver for AbbVie.

Phase 3 design

The above diagram shows the design of two large Phase 3 trials conducted by AbbVie for evaluating Elagolix as a treatment option for endometriosis-associated pain. The primary endpoint was tested at month three, while the secondary endpoint was tested at the end of month six. Elagolix has managed to meet the primary endpoint as well as secondary endpoints in its phase three trials. To know more about the trial results, please refer to Phase 3 Trials Show Elagolix’s Efficacy for Endometriosis Pain.

Elagolix is expected to enable Neurocrine Biosciences to report positive net income in future years, similar to peers such as Amgen (AMGN) and Biogen (BIIB).

If Elagolix manages to get approved by regulatory authorities, it could have a positive impact on share prices of Neurocrine Biosciences as well as those of the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE). Neurocrine Biosciences makes up about 2.7% of PBE’s total portfolio holdings.

In the next article, we’ll explore growth prospects for Elagolix in the uterine fibroids segment.

Advertisement

More From Market Realist